ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell dependent tumor immunity
RNA-seq (gene expression) · mouse · 52 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 52 samples: 52 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 BlockadeCancer immunology research · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE290982_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1231122 and SRA study SRP567695. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 52 sample titles: 52 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8826972 1_1_B
- GSM8826973 1_1_L
- GSM8826974 1_1_T
- GSM8826975 1_2_B
- GSM8826976 1_2_L
- GSM8826977 1_2_T
- GSM8826978 1_3_B
- GSM8826979 1_3_L
- GSM8826980 1_4_B
- GSM8826981 1_4_L
- GSM8826982 1_4_T
- GSM8826983 1_5_B
- GSM8826984 1_5_L
- GSM8826985 1_5_T
- GSM8826986 1_6_S
- GSM8826987 1_7_S
- GSM8826988 1_9_S
- GSM8826989 1_10_S
- GSM8826990 2_1_B
- GSM8826991 2_1_T
- GSM8826992 2_2_B
- GSM8826993 2_2_L
- GSM8826994 2_2_T
- GSM8826995 2_3_B
- GSM8826996 2_3_L
- GSM8826997 2_3_T
- GSM8826998 2_4_B
- GSM8826999 2_4_L
- GSM8827000 2_4_T
- GSM8827001 2_5_B
- GSM8827002 2_5_L
- GSM8827003 2_5_T
- GSM8827004 2_6_S
- GSM8827005 2_7_S
- GSM8827006 2_10_S
- GSM8827007 3_1_B
- GSM8827008 3_1_L
- GSM8827009 3_1_T
- GSM8827010 3_2_L
- GSM8827011 3_2_T
+ 12 more — browse all 52 samples with per-sample file links →
- GSE279659 CD40L-targeting engineered regulatory T cells as a novel cell therapy approach for T cell mediated inflammatory diseases 27 samples shares cd40, targeting
- GSE292938 Targeting the CD40 Co-stimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas 24 samples shares cd40, targeting
- GSE291447 Targeting CD11b+ regulatory B cells via RAS/RAF/PI3K pathway inhibition augments response to immune checkpoint blockade or CD40 agonism in metastatic melanoma 60 samples shares cd40, targeting
- GSE298036 Fc-optimized CD40 Agonistic Antibody Induces Tertiary Lymphoid Structures and Systemic Antitumor Immunity in Metastatic Cancer Patients 33 samples shares cd40, antibody
- GSE248155 Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma 31 samples shares cd40
- GSE248154 Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [4NQO_model] 19 samples shares cd40
- GSE325803 CD40-induced humoral immunity 18 samples shares cd40
- GSE287681 IFN-γ induced the formation of foamy macrophages by CD40 signaling control during Mycobacterium abscessus pulmonary infection 17 samples shares cd40
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.